Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study.

Cancer Immunol Immunother · 2026 · PMC12868551 · PMID 41632305

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

A numerical trend toward longer PFS was also observed with ICI-TKI combinations in both subgroups, more pronounced for intermediate-risk patients.

also in 723 other papers

an overall trendno p-value reported

ICI-TKI) was not significantly associated with PFS (HR 1.18, 95% CI 0.82–1.69, p = 0.37), even when PS-adjusted (HR 1.20, 95% CI 0.83–1.75, p = 0.330), despite an overall trend favoring ICI-TKI, Fig. 4 .

also in 3,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.